QuidelOrtho (US:QDEL)2025-08-05 21:00Financial Performance - Total revenue for Q2 2025 was $614 million, a decrease of 4% year-over-year on a constant currency basis[5] - Adjusted EBITDA for Q2 2025 was $107 million, resulting in a 17% margin[5] - Adjusted diluted EPS for Q2 2025 was $0.12, a 271% increase year-over-year[6] - Year-to-date total revenue was $131 billion, a decrease of 2% year-over-year on a constant currency basis[11] - Year-to-date adjusted EBITDA was $267 million, resulting in a 20% margin[11] - Year-to-date adjusted diluted EPS was $086, a 132% increase year-over-year[11] Revenue Breakdown - North America accounted for 57% of total revenue[7] - Recurring revenue represented 82% of the total revenue[7] - Labs business unit contributed 51% of the total revenue[7] Cash Flow and Balance Sheet - Q2 2025 adjusted free cash flow was negative $32 million[15] - Year-to-date adjusted free cash flow was $15 million[15] - Total debt was $26 billion[15] Financial Guidance for FY 2025 - Total revenues are projected to be between $260 billion and $281 billion[17] - Adjusted EBITDA is expected to be between $575 million and $615 million, with a margin of 22%[17] - Adjusted diluted EPS is projected to be between $207 and $257[17]